Right Hip Intra-Articular Corticosteroid Injection
Hip intra-articular corticosteroid injections must be performed under image guidance—fluoroscopy or ultrasound—due to the joint's depth and proximity to neurovascular structures. 1
Indications
Offer intra-articular corticosteroid injection for:
- Persistent hip osteoarthritis pain unresponsive to first-line treatments (acetaminophen, NSAIDs, physical therapy) 1
- Acute inflammatory flares of hip OA, particularly with effusion 2, 3
- Diagnostic purposes to differentiate intra-articular from extra-articular or spine-related pain (87% sensitivity, 100% specificity) 4
The injection provides time-limited benefit—typically 4-24 weeks—without long-term improvement at 2 years 1.
Contraindications
Absolute contraindications:
- Joint infection or overlying skin infection
- Allergy to corticosteroid or local anesthetic
- Planned joint replacement surgery within 3 months 1
Relative contraindications:
- Poorly controlled diabetes (risk of hyperglycemia) 1
- Immunosuppression (increased infection risk) 5
- Anticoagulation (though bleeding risk is low and most guidelines support continuing anticoagulation) 5
Technique
Image Guidance Selection
Fluoroscopy is preferred as it allows real-time visualization of contrast injection to confirm intra-articular placement and rule out intravascular needle position 5. Fluoroscopy achieves 96-98% accuracy versus 76-88% with ultrasound 5.
Ultrasound is acceptable when fluoroscopy is unavailable, offering advantages of no radiation exposure and visualization of soft tissues 6, 7. However, ultrasound cannot visualize contrast or reliably exclude intravascular injection (reported intravascular rates: 5% fluoroscopy vs 62% ultrasound in one study) 5.
Approach
Three fluoroscopic approaches show equivalent efficacy 8:
- Anterior approach
- Anterolateral approach
- Proximal anterolateral approach
All achieve 80-90% success in one attempt with similar pain scores, radiation exposure, and complication rates 8.
For ultrasound: Use anterosuperior approach with 7 MHz linear or 3.5 MHz convex transducer, advancing a 20-gauge needle into the anterior capsular recess at the femoral head level 7.
Injectate
Corticosteroid options:
- Methylprednisolone (improves pain/function at 4 and 24 weeks) 1
- Triamcinolone (improves pain/function at 6 weeks but not 12 weeks) 1
Local anesthetic is commonly added for immediate pain relief, but use cautiously due to chondrotoxicity concerns 9. Avoid excessive volumes that may cause transient nerve block 5.
Dosage
Standard corticosteroid doses are used, though specific optimal dosing for hip injections lacks definitive evidence 5. Low-dose prednisone equivalent (10-20 mg) may be considered for grade 1 inflammatory arthritis 2.
Post-Procedure Care
Immediate monitoring:
- Observe for vasovagal reaction (2.5% incidence) 5
- Assess for immediate adverse events: injection site pain, facial flushing/sweating (corticosteroid effect), transient nerve block if local anesthetic used 5
Patient education:
- Expect injection site soreness (most common delayed adverse event) 5
- Monitor diabetic patients for hyperglycemia 1
- Report signs of infection immediately (rare but serious: <1% risk) 5
Repeat injections: Consider repeat injection only if:
- ≥75% relief from initial diagnostic injection, OR
- ≥50% relief lasting ≥2 months suggesting steroid benefit 5
Caution with repeated injections: Potential long-term negative effects on bone health, joint structure, and cartilage thickness 1. Recent reports suggest possible accelerated OA progression or subchondral insufficiency fracture with repeated injections, though causality remains unclear 10.
Critical Pitfalls
- Never perform blind hip injections—accuracy is poor and risks neurovascular injury 1, 5
- Avoid injection within 3 months of planned arthroplasty—increased infection risk 1
- Do not use hyaluronic acid for hip OA—strong recommendation against it 11, 3
- Recognize limited durability—effects are time-limited; this is not disease-modifying therapy 1
- Screen for diabetes and optimize glucose control before injection 1